CareDx, Inc. (CDNA)

Insider Trading Filed: 2026-05-06

Jeffrey Adam Novack, Secretary and General Counsel of CareDx, sold 2,688 shares on May 5, 2026 at a weighted average price of $20.68, representing a planned divestment under a Rule 10b5-1 trading plan adopted in September 2025.
The insider's remaining beneficial ownership of 113,924 shares indicates a substantial retained stake, suggesting continued confidence despite the planned stock sale.
The use of a pre-established 10b5-1 trading plan demonstrates this was a scheduled, systematic sale rather than a sudden liquidation, reducing concerns about loss of confidence in the company's near-term prospects.
The sale amount (~$55,500) is relatively modest compared to the insider's total holdings, suggesting this is routine portfolio rebalancing rather than a significant exit by a key officer.

Insider Trading Filed: 2026-05-04

Secretary and General Counsel Jeffrey Adam Novack disposed of 2,873 shares on 05/01/2026 at $21.50 per share through a tax withholding arrangement related to restricted stock unit vesting, indicating routine equity compensation execution rather than a discretionary sale.
Following the transaction, Novack maintains direct beneficial ownership of 116,612 shares of CDNA common stock, demonstrating continued significant insider holdings and alignment with shareholder interests despite the modest disposition.
The transaction was executed via Rule 10b5-1(c) compliant mechanism (tax withholding), which is a standard, pre-planned arrangement for equity-based compensation and carries no negative inference regarding insider confidence in the company.

Quarterly Report Filed: 2026-04-28

The filing shows CareDx operates across three business segments (Services, Products, and Patient & Digital Solutions) with diversified revenue streams, reducing dependency on any single segment.
The company maintains significant litigation exposure including a patent dispute with Natera Inc. and securities class action lawsuits, which could impact future financial performance and cash flow.
CareDx has active equity incentive programs and a May 2025 share repurchase authorization, indicating management confidence in valuation while maintaining employee retention through stock-based compensation.
The company's balance sheet includes intangible assets from acquisitions (technology, customer relationships, commercialization rights), suggesting growth through M&A strategy with associated integration risks.

Current Report Filed: 2026-04-28

CareDx is acquiring Naveris, Inc. for $160 million in upfront cash consideration with up to $100 million in earn-out payments tied to revenue milestones in 2026-2027, representing a significant strategic expansion of the company's capabilities.
The transaction includes customary closing conditions including HSR antitrust review clearance and a termination date of October 28, 2026, with a $5 million escrow deposit to secure post-closing adjustments, indicating standard deal structure and governance.
CareDx simultaneously released Q1 2026 financial results and an updated corporate presentation on April 28, 2026, suggesting the company is communicating broader strategic positioning alongside the acquisition announcement to investors.

Insider Trading Filed: 2026-04-22

CFO & COO Kennedy Keith acquired 24,134 RSUs (restricted stock units) on April 20, 2026, with a $0 grant price, indicating a compensation award rather than market purchase.
The RSU vesting schedule spans 3 years with one-third vesting on April 6, 2027, followed by eight equal quarterly installments, demonstrating a long-term retention incentive aligned with executive continuity.
Following this transaction, Keith's total beneficial ownership reached 221,548 shares, reflecting significant personal stake in the company's performance as a senior executive.
The filing was executed by attorney-in-fact Jeffrey Adam Novack on April 22, 2026, two days after the transaction date, indicating standard administrative processing of executive compensation.

Insider Trading Filed: 2026-04-16

John Walter Hanna Jr., the President and CEO of CareDx, Inc., disposed of 62,049 shares of common stock on April 15, 2026, likely to satisfy tax withholding obligations related to the vesting of restricted stock units.
Following the transaction, Hanna still holds a significant stake of 686,757 shares, indicating his continued commitment to the company.
The timing of the transaction and the relatively small amount of shares disposed compared to Hanna's total holdings suggest this is a routine transaction and not indicative of any major concerns or changes in his outlook for the company.

Current Report Filed: 2026-04-16

CareDx, Inc. has entered into a definitive agreement to sell its CareDx AB subsidiary and certain assets related to its kitted laboratory products business to Eurobio Scientific S.A. for $170 million in cash.
The transaction will allow CareDx to focus on its core transplant diagnostics business, while Eurobio will gain access to CareDx's technology and product portfolio in the US, Canada, and Mexico markets.
CareDx also provided preliminary Q1 2026 financial results, indicating strong performance with revenue and profitability metrics exceeding expectations.

Insider Trading Filed: 2026-04-07